Eledon Pharmaceuticals (ELDN) Equity Ratio (2013 - 2026)

Eledon Pharmaceuticals has reported Equity Ratio for 14 years, with the latest figure at 0.31 in Q1 2026.

• For the quarter ending Q1 2026, Equity Ratio fell 16.39% year-over-year to 0.31; the trailing twelve-month figure through Mar 2026 stood at 0.31 (down 16.39% YoY), and the FY2025 full-year result was 0.48, up 36.3% from the prior year.
• Equity Ratio for Q1 2026 stood at 0.31, down from 0.48 in the prior quarter.
• The five-year high for Equity Ratio was 0.97 in Q1 2022, with the low at 0.87 in Q1 2024.
• Historically, Equity Ratio has averaged 0.3 across 5 years, with a median of 0.35 in 2024.
• Annual changes were most pronounced in 2023 — Equity Ratio tumbled 312.35% — and 2025, when it soared 165.19%.
• Eledon Pharmaceuticals' Equity Ratio stood at 0.26 in 2022, then plunged by 312.35% to 0.54 in 2023, then soared by 164.66% to 0.35 in 2024, then soared by 36.3% to 0.48 in 2025, then slumped by 36.38% to 0.31 in 2026.
• The last three Equity Ratio figures came in at 0.31 (Q1 2026), 0.48 (Q4 2025), and 0.27 (Q3 2025), per Business Quant data.